Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 18/20 | 0.56 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.53 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21753394 | 0.91 | STING1 (0.54) | STING1TBK1ENPP1 | |
| SCHEMBL30882065 | 0.91 | STING1 (0.54) | STING1TBK1ENPP1 | |
| SCHEMBL21766106 | 0.91 | STING1 (0.55) | STING1TBK1ENPP1 | |
| SCHEMBL21766327 | 0.90 | STING1 (0.53) | STING1TBK1ENPP1 | |
| SCHEMBL21753415 | 0.87 | STING1 (0.51) | STING1TBK1ENPP1 | |
| SCHEMBL21753433 | 0.87 | STING1 (0.55) | STING1TBK1ENPP1 | |
| SCHEMBL21766138 | 0.86 | STING1 (0.51) | STING1TBK1ENPP1 | |
| SCHEMBL21766149 | 0.85 | ENPP1 (0.48) | STING1TBK1ENPP1 | |
| SCHEMBL23585738 | 0.85 | STING1 (0.52) | STING1ENPP1 | |
| SCHEMBL24467551 | 0.84 | STING1 (0.58) | STING1TBK1ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287093-A1 | HIGH ACTIVITY STING PROTEIN AGONIST | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2024-08-29 | — | — | US | disclosed |
| EP-3842437-B1 | HIGH ACTIVITY STING PROTEIN AGONIST | ADLAI NORTYE BIOPHARMA CO LTD (CN) | 2024-04-10 | — | — | EP | disclosed |
| CN-111386275-B | High activity STING protein agonists | 杭州阿诺生物医药科技有限公司 | 2023-03-10 | — | — | CN | disclosed |
| EP-3842437-A1 | HIGH ACTIVITY STING PROTEIN AGONIST | Adlai Nortye Biopharma Co., Ltd. (CN) | 2021-06-30 | — | — | EP | disclosed |
| EP-3842437-A1 | HIGH ACTIVITY STING PROTEIN AGONIST | Adlai Nortye Biopharma Co., Ltd. (CN) | 2021-06-30 | — | — | EP | disclosed |
| CN-111386275-A | High activity STING protein agonists | 杭州阿诺生物医药科技有限公司 | 2020-07-07 | — | — | CN | disclosed |
| WO-2020038387-A1 | HIGH ACTIVITY STING PROTEIN AGONIST | 杭州阿诺生物医药科技有限公司 | 2020-02-27 | — | — | WO | disclosed |
| WO-2020038387-A1 | HIGH ACTIVITY STING PROTEIN AGONIST | 杭州阿诺生物医药科技有限公司 | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287093-A1 | HIGH ACTIVITY STING PROTEIN AGONIST | STING1, IRF3, MAVS | STING1 1/4885TBK1 5/4885ENPP1 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.